Union Bancaire Privee UBP SA Invests $225,000 in DexCom, Inc. (NASDAQ:DXCM)

Union Bancaire Privee UBP SA acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,000 shares of the medical device company’s stock, valued at approximately $225,000.

A number of other hedge funds also recently made changes to their positions in DXCM. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter valued at about $25,000. Riverview Trust Co raised its position in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in shares of DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new position in DexCom in the 3rd quarter worth approximately $57,000. Finally, Park Place Capital Corp grew its stake in DexCom by 3,516.7% in the 4th quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock valued at $68,000 after buying an additional 844 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price target on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Wells Fargo & Company lifted their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Royal Bank of Canada reduced their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Citigroup increased their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Stock Performance

Shares of DexCom stock opened at $86.43 on Thursday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a market capitalization of $33.76 billion, a P/E ratio of 51.75, a P/E/G ratio of 2.23 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business has a fifty day simple moving average of $80.00 and a two-hundred day simple moving average of $76.52.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.